Laboratory Corporation of America Holdings announced the expansion of its drug development offering in the Asia-Pacific region with the addition of bioanalytical services in Singapore. The new bioanalytical laboratory in Singapore will support the development of both small and large molecular entities while providing a complete range of regulated and non-regulated bioanalytical services. Bioanalytics is a quantitative measure of drugs and metabolites in biological samples such as blood, serum, tissue and plasma. The laboratory will offer Good Laboratory Practice and Good Clinical Practice-compliant bioanalysis, liquid chromatography-mass spectometry and immunochemistry platforms, as well as discovery and clinical biomarker analytical services. In addition, it will allow faster data turnaround for early phase trials in Asia-Pacific markets. Construction and reconfiguration of the bioanalytical laboratory has commenced, and its opening is expected in late 2021.